Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
94.59
+1.59 (1.71%)
Mar 17, 2026, 2:53 PM EDT - Market open
Incyte Employees
Incyte had 2,844 employees as of December 31, 2025. The number of employees increased by 227 or 8.67% compared to the previous year.
Employees
2,844
Change (1Y)
227
Growth (1Y)
8.67%
Revenue / Employee
$1,807,750
Profits / Employee
$452,409
Market Cap
18.82B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,844 | 227 | 8.67% |
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
| BridgeBio Pharma | 839 |
INCY News
- 4 hours ago - Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue - Seeking Alpha
- 7 hours ago - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico - GlobeNewsWire
- 7 hours ago - Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil - GlobeNewsWire
- 23 hours ago - Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond - Seeking Alpha
- 6 days ago - Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 days ago - Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 10 days ago - Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - Business Wire
- 14 days ago - Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha